A股異動 | 冠昊生物大漲近8% 子公司承擔國家科技重大專項任務
格隆匯12月20日丨冠昊生物(300238.SZ)今日大幅高開上漲,一度封漲停。現報20.59元,漲7.8%,暫成交1.45億元,最新總市值54.6億元。冠昊生物昨日公告,子公司承擔“十三五”“重大新藥創制”國家科技重大專項任務。課題名稱為“1類化學新藥苯烯莫德乳膏治療兒童濕疹的臨牀研究”。另外,在5月7日至12月17日期間,獲控股股東通過二級市場集中競價方式累計增持公司股份265.2432萬股,增持比例達到公司總股本的1%。公司是一家從事再生醫學材料及再生型醫用植入器械研發、生產及銷售的高科技企業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.